{"id":35579,"date":"2025-11-12T17:41:45","date_gmt":"2025-11-12T22:41:45","guid":{"rendered":"https:\/\/joinastudy.ca\/?p=35579"},"modified":"2025-12-09T12:51:50","modified_gmt":"2025-12-09T17:51:50","slug":"glp-1-agonists-looking-to-the-future","status":"publish","type":"post","link":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-looking-to-the-future\/","title":{"rendered":"GLP-1 Agonists: Looking to the Future"},"content":{"rendered":"

Following the success of Ozempic\u00ae<\/a>, Wegovy\u00ae<\/a>, and other GLP-1 receptor agonists, pharmaceutical companies are racing to develop the next wave of metabolic drugs. These new therapies build on the proven benefits of currently approved GLP-1s\u2014lowering blood sugar, supporting weight loss, and reducing cardiovascular risk\u2014while aiming for even greater results in weight management and metabolic health.<\/p>\n

The table below highlights some of the most promising GLP-1 drugs and multi-agonist combinations currently in clinical development, the companies behind them, and the additional health conditions they\u2019re being studied for. From oral GLP-1s to triple-action molecules targeting obesity, fatty liver disease, and cardiovascular outcomes, these next-generation treatments could reshape the future of diabetes and obesity care.<\/p>\n

\n
\n\n\n\n\n\n\n\n\n\n\n
Drug Candidate<\/th>\nCompany \/ Sponsor<\/th>\nMechanism \/ Targets<\/th>\nIndications Being Tested<\/th>\nClinical Phase & Highlights<\/th>\n<\/tr>\n<\/thead>\n
Orforglipron<\/strong><\/td>\nEli Lilly and Company<\/a><\/td>\nOral, small-molecule GLP-1 receptor agonist<\/td>\nType 2 diabetes; Obesity\/weight-management<\/td>\nPhase 3: in the ACHIEVE-1 trial (T2D) showed ~1.3\u20131.6 % HbA1c reduction at 40 weeks, and ~7.9 % body-weight loss in highest dose arm.<\/td>\n<\/tr>\n
Retatrutide<\/strong> (LY-3437943)<\/td>\nEli Lilly<\/a><\/td>\nTriple agonist: GLP-1 + GIP + Glucagon receptors<\/td>\nObesity; Type 2 diabetes; Fatty liver disease (MASLD\/NASH)<\/td>\nPhase 2\/3: In a 48-week obesity study, doses 8 mg & 12 mg achieved ~22.8\u201324.2% weight loss; in a liver-fat substudy in MASLD, >80 % reduction in liver fat at 24\u201348 weeks.<\/td>\n<\/tr>\n
CagriSema<\/strong> (combination semaglutide + cagrilintide)<\/td>\nNovo Nordisk<\/a><\/td>\nDual agonist: GLP-1 + Amylin analog (cagrilintide)<\/td>\nObesity \/ weight management; Metabolic disease<\/td>\nUnder development (late-stage) \u2014 aims to enhance weight-loss efficacy beyond standalone GLP-1.<\/td>\n<\/tr>\n
Amycretin<\/strong><\/td>\nNovo Nordisk<\/a><\/td>\nDual agonist: GLP-1 + Amylin (experimental)<\/td>\nObesity; Metabolic disorders<\/td>\nEarly to mid\u2010stage trials.<\/td>\n<\/tr>\n
Survodutide<\/strong><\/td>\nZealand Pharma<\/a> (with Boehringer Ingelheim<\/a>)<\/td>\nGLP-1 + Glucagon receptor co-agonist<\/td>\nObesity; Non-alcoholic steatohepatitis (NASH<\/a>)<\/td>\nIn development \u2014 exploring metabolic\/liver-disease indications.<\/td>\n<\/tr>\n
Danuglipron<\/strong><\/td>\nPfizer<\/a><\/td>\nOnce-daily oral GLP-1 receptor agonist<\/td>\nObesity \/ weight loss<\/td>\nDevelopment terminated Apr-2025 due to a liver-injury safety signal.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n

These drugs reflect major shifts: from injectable only to oral formulations (e.g., Orforglipron); and from single-target (GLP-1) to multi-agonist (GLP-1 + GIP, GLP-1 + Glucagon, GLP-1 + Amylin) aiming for stronger weight-loss and broader metabolic effects. Their indication expansion is broadening: beyond T2DM and obesity to include MASLD\/NASH<\/a>, cardiovascular disease<\/a>, kidney disease<\/a>, and fatty-liver\/steatosis<\/a>. For example, Retatrutide showed marked liver-fat reduction in a MASLD subgroup.<\/p>\n

An additional note for Orforglipron: Eli Lilly expects regulatory filings toward late-2025 (obesity) and possibly 2026 (diabetes) based on clinical results.<\/p>\n

As we can see from the final drug listed in the table above, not all testing pipelines result in success: Danuglipron\u2019s termination underscores that safety (e.g., liver injury) and tolerability remain critical obstacles to the approval of new GLP-1s.<\/p>\n

These developments have implications for future treatment paradigms: improved convenience (oral), wider access global scale, more powerful weight-loss, and potentially new classes of metabolic disease therapies.<\/p>\n

In Part 4<\/strong>, we\u2019ll review some of the most Frequently Asked Questions regarding GLP-1s, and their answers. It\u2019s releasing exclusively on our blog November 14th, so make sure to add us to your bookmarks to stay up to date!:
\nhttps:\/\/joinastudy.ca\/canadian-health-blog\/<\/a><\/p>\n

Sources<\/span><\/b>\u00a0<\/span><\/p>\n

https:\/\/my.clevelandclinic.org\/health\/treatments\/13901-glp-1-agonists<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medeffect-canada\/health-product-infowatch\/december-2024.html<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/pubmed.ncbi.nlm.nih.gov\/26371721\/<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.endocrinologyadvisor.com\/ddi\/glp-1-agonists\/<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/hopkinsdiabetesinfo.org\/medications-for-type-2-diabetes-glp-1-agonists\/<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551568\/<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/books\/n\/rc72848269830370\/<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/drug-shortages\/information-consumers\/supply-notices\/ozempic.html<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.practicenursing.com\/content\/clinical\/glp-1-receptor-agonists-and-their-role-in-managing-type-2-diabetes<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.drugs.com\/medical-answers\/glp-1-drug-best-weight-loss-3579236\/<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.primetherapeutics.com\/en\/glp-1-pipeline-update-november-2024<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/drug-shortages\/information-consumers\/supply-notices\/ozempic.html\/1000.html<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.avalanchept.com\/post\/comprehensive-list-of-fda-approved-glp-1-receptor-agonists-as-of-mid-2025<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.powerpak.com\/course\/content\/118150<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.powerpak.com\/course\/content\/114864<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.primetherapeutics.com\/glp-1-pipeline-update-february-2025<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/primetherapeutics.com\/glp-1-pipeline-update-may-2025<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/primetherapeutics.com\/glp-1-pipeline-november-2024<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.primetherapeutics.com\/glp-1-pipeline-update-november-2024<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.beckershospitalreview.com\/glp-1s\/glp-1-drug-approvals-a-breakdown.html<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/acgng.org\/most-popular-glp-1-medications\/<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/sanemd.com\/glp-1-medications\/glp-1-medications-list-benefits-uses-side-effects\/<\/span><\/b><\/a>\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Following the success of Ozempic\u00ae, Wegovy\u00ae, and other GLP-1 receptor agonists, pharmaceutical companies are racing to develop the next wave of metabolic drugs. These new therapies build on the proven benefits of currently approved GLP-1s\u2014lowering blood sugar, supporting weight loss, and reducing cardiovascular risk\u2014while aiming for even greater results in weight management and metabolic health.<\/p>\n","protected":false},"author":964,"featured_media":32967,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[603,605,487,489,513],"tags":[],"class_list":["post-35579","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-obesity-weight-loss","category-diabetes","category-drug-development","category-industry-news","category-health-and-wellness","category-603","category-605","category-487","category-489","category-513","description-off"],"acf":[],"yoast_head":"\nGLP-1s: The Next Generation of Diabetes Treatments - JoinAStudy.ca<\/title>\n<meta name=\"description\" content=\"Discover how new GLP-1s are transforming diabetes care and weight loss with innovative treatments now in development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-looking-to-the-future\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GLP-1 Agonists: Looking to the Future\" \/>\n<meta property=\"og:description\" content=\"Discover how new GLP-1s are transforming diabetes care and weight loss with innovative treatments now in development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-looking-to-the-future\/\" \/>\n<meta property=\"og:site_name\" content=\"JoinAStudy.ca\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/joinastudy.ca\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-12T22:41:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-09T17:51:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/joinastudy.ca\/wp-content\/uploads\/White-and-Blue-Photo-Medical-Facebook-Cover.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1640\" \/>\n\t<meta property=\"og:image:height\" content=\"924\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"JoinAStudy Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@JoinAStudy_ca\" \/>\n<meta name=\"twitter:site\" content=\"@JoinAStudy_ca\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"JoinAStudy Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-looking-to-the-future\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-looking-to-the-future\\\/\"},\"author\":{\"name\":\"JoinAStudy Team\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#\\\/schema\\\/person\\\/da824a10716e724d72676ec94d865d71\"},\"headline\":\"GLP-1 Agonists: Looking to the Future\",\"datePublished\":\"2025-11-12T22:41:45+00:00\",\"dateModified\":\"2025-12-09T17:51:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-looking-to-the-future\\\/\"},\"wordCount\":667,\"publisher\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-looking-to-the-future\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/White-and-Blue-Photo-Medical-Facebook-Cover.png\",\"articleSection\":[\"Obesity & Weight Loss\",\"Diabetes\",\"Drug Development\",\"Industry News\",\"Health and Wellness\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-looking-to-the-future\\\/\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-looking-to-the-future\\\/\",\"name\":\"GLP-1s: The Next Generation of Diabetes Treatments - JoinAStudy.ca\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-looking-to-the-future\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-looking-to-the-future\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/White-and-Blue-Photo-Medical-Facebook-Cover.png\",\"datePublished\":\"2025-11-12T22:41:45+00:00\",\"dateModified\":\"2025-12-09T17:51:50+00:00\",\"description\":\"Discover how new GLP-1s are transforming diabetes care and weight loss with innovative treatments now in development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-looking-to-the-future\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-looking-to-the-future\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-looking-to-the-future\\\/#primaryimage\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/White-and-Blue-Photo-Medical-Facebook-Cover.png\",\"contentUrl\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/White-and-Blue-Photo-Medical-Facebook-Cover.png\",\"width\":1640,\"height\":924,\"caption\":\"hypertriglyceridemia, GLP-1s\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-looking-to-the-future\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GLP-1 Agonists: Looking to the Future\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/\",\"name\":\"JoinAStudy.ca\",\"description\":\"JoinAStudy.ca - Help create a healthier future\",\"publisher\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#organization\",\"name\":\"JoinAStudy.ca\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/JoinaStudy-Logo-Mobile-e1520526932796.png\",\"contentUrl\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/JoinaStudy-Logo-Mobile-e1520526932796.png\",\"width\":118,\"height\":65,\"caption\":\"JoinAStudy.ca\"},\"image\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/joinastudy.ca\",\"https:\\\/\\\/x.com\\\/JoinAStudy_ca\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UC_ed0XmzH5ImSNOEJcdXKqg\"],\"publishingPrinciples\":\"https:\\\/\\\/joinastudy.ca\\\/why-join-a-study\\\/\",\"ownershipFundingInfo\":\"https:\\\/\\\/joinastudy.ca\\\/information-disclaimer\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#\\\/schema\\\/person\\\/da824a10716e724d72676ec94d865d71\",\"name\":\"JoinAStudy Team\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/author\\\/grant\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GLP-1s: The Next Generation of Diabetes Treatments - JoinAStudy.ca","description":"Discover how new GLP-1s are transforming diabetes care and weight loss with innovative treatments now in development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-looking-to-the-future\/","og_locale":"fr_FR","og_type":"article","og_title":"GLP-1 Agonists: Looking to the Future","og_description":"Discover how new GLP-1s are transforming diabetes care and weight loss with innovative treatments now in development.","og_url":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-looking-to-the-future\/","og_site_name":"JoinAStudy.ca","article_publisher":"https:\/\/www.facebook.com\/joinastudy.ca","article_published_time":"2025-11-12T22:41:45+00:00","article_modified_time":"2025-12-09T17:51:50+00:00","og_image":[{"width":1640,"height":924,"url":"https:\/\/joinastudy.ca\/wp-content\/uploads\/White-and-Blue-Photo-Medical-Facebook-Cover.png","type":"image\/png"}],"author":"JoinAStudy Team","twitter_card":"summary_large_image","twitter_creator":"@JoinAStudy_ca","twitter_site":"@JoinAStudy_ca","twitter_misc":{"\u00c9crit par":"JoinAStudy Team","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-looking-to-the-future\/#article","isPartOf":{"@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-looking-to-the-future\/"},"author":{"name":"JoinAStudy Team","@id":"https:\/\/joinastudy.ca\/fr\/#\/schema\/person\/da824a10716e724d72676ec94d865d71"},"headline":"GLP-1 Agonists: Looking to the Future","datePublished":"2025-11-12T22:41:45+00:00","dateModified":"2025-12-09T17:51:50+00:00","mainEntityOfPage":{"@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-looking-to-the-future\/"},"wordCount":667,"publisher":{"@id":"https:\/\/joinastudy.ca\/fr\/#organization"},"image":{"@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-looking-to-the-future\/#primaryimage"},"thumbnailUrl":"https:\/\/joinastudy.ca\/wp-content\/uploads\/White-and-Blue-Photo-Medical-Facebook-Cover.png","articleSection":["Obesity & Weight Loss","Diabetes","Drug Development","Industry News","Health and Wellness"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-looking-to-the-future\/","url":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-looking-to-the-future\/","name":"GLP-1s: The Next Generation of Diabetes Treatments - JoinAStudy.ca","isPartOf":{"@id":"https:\/\/joinastudy.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-looking-to-the-future\/#primaryimage"},"image":{"@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-looking-to-the-future\/#primaryimage"},"thumbnailUrl":"https:\/\/joinastudy.ca\/wp-content\/uploads\/White-and-Blue-Photo-Medical-Facebook-Cover.png","datePublished":"2025-11-12T22:41:45+00:00","dateModified":"2025-12-09T17:51:50+00:00","description":"Discover how new GLP-1s are transforming diabetes care and weight loss with innovative treatments now in development.","breadcrumb":{"@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-looking-to-the-future\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/joinastudy.ca\/fr\/glp-1-agonists-looking-to-the-future\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-looking-to-the-future\/#primaryimage","url":"https:\/\/joinastudy.ca\/wp-content\/uploads\/White-and-Blue-Photo-Medical-Facebook-Cover.png","contentUrl":"https:\/\/joinastudy.ca\/wp-content\/uploads\/White-and-Blue-Photo-Medical-Facebook-Cover.png","width":1640,"height":924,"caption":"hypertriglyceridemia, GLP-1s"},{"@type":"BreadcrumbList","@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-looking-to-the-future\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/joinastudy.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"GLP-1 Agonists: Looking to the Future"}]},{"@type":"WebSite","@id":"https:\/\/joinastudy.ca\/fr\/#website","url":"https:\/\/joinastudy.ca\/fr\/","name":"JoinAStudy.ca","description":"JoinAStudy.ca - Help create a healthier future","publisher":{"@id":"https:\/\/joinastudy.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/joinastudy.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/joinastudy.ca\/fr\/#organization","name":"JoinAStudy.ca","url":"https:\/\/joinastudy.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/joinastudy.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/joinastudy.ca\/wp-content\/uploads\/JoinaStudy-Logo-Mobile-e1520526932796.png","contentUrl":"https:\/\/joinastudy.ca\/wp-content\/uploads\/JoinaStudy-Logo-Mobile-e1520526932796.png","width":118,"height":65,"caption":"JoinAStudy.ca"},"image":{"@id":"https:\/\/joinastudy.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/joinastudy.ca","https:\/\/x.com\/JoinAStudy_ca","https:\/\/www.youtube.com\/channel\/UC_ed0XmzH5ImSNOEJcdXKqg"],"publishingPrinciples":"https:\/\/joinastudy.ca\/why-join-a-study\/","ownershipFundingInfo":"https:\/\/joinastudy.ca\/information-disclaimer\/"},{"@type":"Person","@id":"https:\/\/joinastudy.ca\/fr\/#\/schema\/person\/da824a10716e724d72676ec94d865d71","name":"JoinAStudy Team","url":"https:\/\/joinastudy.ca\/fr\/author\/grant\/"}]}},"_links":{"self":[{"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/posts\/35579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/users\/964"}],"replies":[{"embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/comments?post=35579"}],"version-history":[{"count":3,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/posts\/35579\/revisions"}],"predecessor-version":[{"id":35655,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/posts\/35579\/revisions\/35655"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/media\/32967"}],"wp:attachment":[{"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/media?parent=35579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/categories?post=35579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/tags?post=35579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}